Drug intelligence / Profile preview

sofosbuvir + ribavirin + Stribild

Development stage: Preclinical
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

This is a combination treatment regimen used for patients co-infected with hepatitis C virus (HCV) and HIV. It combines sofosbuvir (an HCV NS5B polymerase inhibitor), ribavirin (a nucleoside analog with antiviral activity against HCV), and Stribild (a complete HIV treatment regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate). This combination would be used to simultaneously treat both HCV and HIV infections in co-infected patients.

Targets

ABCB1 (P-glycoprotein)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)Human immunodeficiency virus type 1 reverse transcriptaseCYP2D6 (Cytochrome P450 2D6)ABCG2 (Breast cancer resistance protein)OATP1B1 (Organic anion transporting polypeptide 1B1)SLC47A1 (Multidrug and toxin extrusion transporter 1)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)SLCO1B3 (Organic anion transporting polypeptide 1B3)Integrase allosteric pocket (HIV)CYP3A (CYP3A family)

Beyond the preview

Go deeper on sofosbuvir + ribavirin + Stribild.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sofosbuvir + ribavirin + Stribild.

Explore the full profile